Striking randomly, traumatic brain injury (TBI) is a """"""""silent epidemic"""""""" which affects two to four million persons each year. The consequences of TBI in these patients, having a mean age of 29.5 years, pose a tremendous loss to family and society in terms of potential productive years of life. Unfortunately, no effective therapies for human head injury are available. The injury to the CNS can be categorized as either primary or secondary. Primary injury results from immediately physical damage as a consequence of trauma and is difficult, it not impossible, to prevent. Secondary injuries are delayed pathological events occurring within minutes, hours, or days after the primary trauma and lead to further damage of the nervous system. Inflammatory responses are major components of secondary injury and are thought to be key contributors to TBI pathophysiology. Prostaglandins, potent mediators of inflammation, are produced via the action of cyclooxygenase-1 and 2 [Cox-1 and COX-2, also known as PGH synthase 1 and 2]. Cox-1 is constitutively expressed in most tissue and is responsible for the physiological production of prostaglandins. In contrast, COX-2 is inducible and is responsible for the elevated production of prostaglandins. A considerable amount of evidence from several experimental systems indicates that COX-2 plays a critical role in inflammation. However, the mechanism(s) of inflammatory responses following TBI has not been elucidated. Our preliminary studies indicate that enhanced Cox-2 expression is associated with experimental TBI. Based on these and other findings, the proposal has three specific aims: (1) to test the hypothesis that induction of Cox-2 contributes to TBI pathophysiology, (2) to test the hypothesis that TBI-induced activation of NFkappaB [nuclear factor kappa B], ATF [activating transcription factor], and/or C/EBP [CCAAT/enhancer binding protein] lead to Cox-2 induction; and (3) to test the hypothesis that the anti- inflammatory agents methylprednisolone and IL-10 attenuate Cox-2 expression. The experiments outlined in this proposal will provide a unique opportunity to both unravel the cellular and molecular mechanisms of TBI- induced inflammation and provide the foundation for therapeutic strategies which will be invaluable in the treatment of TBI.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
2P50NS023327-14
Application #
6112247
Study Section
Project Start
1999-02-01
Project End
2000-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
14
Fiscal Year
1999
Total Cost
Indirect Cost
City
Houston
State
TX
Country
United States
Zip Code
77225
Chen, Pei-Feng; Wu, Kenneth K (2009) Two synthetic peptides corresponding to the proximal heme-binding domain and CD1 domain of human endothelial nitric-oxide synthase inhibit the oxygenase activity by interacting with CaM. Arch Biochem Biophys 486:132-40
Wu, Jui-Sheng; Cheung, Wai-Mui; Tsai, Yau-Sheng et al. (2009) Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 119:1124-34
Liou, Jun-Yang; Ellent, David P; Lee, Sang et al. (2007) Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis. Stem Cells 25:1096-103
Liou, Jun-Yang; Lee, Sang; Ghelani, Dipak et al. (2006) Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 26:1481-7
Cieslik, Katarzyna A; Deng, Wu-Guo; Wu, Kenneth K (2006) Essential role of C-Rel in nitric-oxide synthase-2 transcriptional activation: time-dependent control by salicylate. Mol Pharmacol 70:2004-14
Deng, Wu-Guo; Tang, Shao-Tzu; Tseng, Hui-Ping et al. (2006) Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 108:518-24
Wu, Kenneth K (2006) Analysis of protein-DNA binding by streptavidin-agarose pulldown. Methods Mol Biol 338:281-90
Lin, Teng-Nan; Cheung, Wai-Mui; Wu, Jui-Sheng et al. (2006) 15d-prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 26:481-7
Wu, Kenneth K (2006) Transcription-based COX-2 inhibition: a therapeutic strategy. Thromb Haemost 96:417-22
Liou, Jun-Yang; Aleksic, Nena; Chen, Shu-Fen et al. (2005) Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance. Exp Cell Res 306:75-84

Showing the most recent 10 out of 63 publications